NCT02432963View on ClinicalTrials.gov

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 14, 2016

Primary Completion Date

December 4, 2017

Study Completion Date

October 31, 2025

Conditions
Adult Solid NeoplasmBladder CarcinomaColon CarcinomaEstrogen Receptor NegativeHead and Neck Squamous Cell CarcinomaHepatocellular CarcinomaHER2/Neu NegativeMelanomaNon-Small Cell Lung CarcinomaPancreatic CarcinomaProgesterone Receptor NegativeRectal CarcinomaRenal Cell CarcinomaSoft Tissue SarcomaTriple-Negative Breast CarcinomaTP53 Gene MutationUnresectable Solid Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Modified Vaccinia Virus Ankara Vaccine Expressing p53

Given SC

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER